Current optimal chemotherapy for advanced urothelial cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 1, 2008, Pages 51-61

  Sonpavde, Guru ^a   Galsky, Matthew D ^a   Hutson, Thomas E ^b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced urothelial cancer; Chemotherapy; Transitional cell carcinoma; Urothelial cancer

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; E 7389; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IXABEPILONE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PACLITAXEL DERIVATIVE; PAZOPANIB; PEMETREXED; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VINBLASTINE; VINFLUNINE;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; KIDNEY FAILURE; LUNG TOXICITY; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINARY TRACT CARCINOMA; METASTASIS; PATHOLOGY; URINARY TRACT CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; UROLOGIC NEOPLASMS;

EID: 38349011315     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.1.51     Document Type: Review

References (74)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64(12), 2448-2458 (1989).
3. Dodd PM, McCaffrey JA, Herr H et al. Outcome of post-chemotherapy surgery following treatment with methotrexate, vinblastine, adriamycin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin. Oncol. 17, 2546-2552 (1999).
4. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10(7), 1066-1073 (1992).
5. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 17, 3068-3077 (1997).
6. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050-1055 (1990).
7. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 22(2), 220-228 (2004).
8. Siefker-Radtke AO, Millikan RE, Tu SM et al. Phase III trial of fluorouracil, interferon alfa-2b and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in metastatic or unresectable urothelial cancer. J. Clin. Oncol. 20(5), 1361-1367 (2002).
9. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cyscectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003). Erratum in: N. Engl. j. Med. 349(19), 1880 (2003).
10. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17, 3173-3181 (1999).
11. Bellmunt J, von der Maase H, Mead GM et al. Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/ cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J. Clin. Oncol. 2007 ASCO Annual Meeting proceedings 25(Suppl. 18), LBA5030 (2007).
12. Bajorin DF, Ostrovnaya I, Iasonos A et al. A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy. J. Clin. Oncol. 25(Suppl. 18), 5055 (2007).
13. Logothetis CJ, Dexeus FH, Sella A et al. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J. Natl Cancer Inst. 82, 667-672 (1990).
14. Loehrer PJ Sr, Elson F, Dreicer R et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology-Group trial. J. Clin. Oncol. 12, 483-488 (1994).
15. Seidman AD, Scher HI, Gabrilove JL et al. Dose-intensification of methotrexate, vinblastine, doxorubicin, and cisplatin with recombinant granulocyte-colony stimulating factor as initial therapy in advanced urothelial cancer. J. Clin. Oncol. 11, 414-420 (1992).
16. Sternberg CN, de Mulder PH, van Oosterom AT et al. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann. Oncol. 4, 403-407 (1993).
17. Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC Phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42(1), 50-54 (2006).
18. Stadler WM, Kuzel T, Roth B et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. 15, 3394-3398 (1997).
19. Lorusso V, Pollera CF, Antimi M et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer 34(8), 1208-1212 (1998).
20. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18, 1921-1927 (2000).
21. Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17, 2876-2881 (1999).
22. von der Maase H, Andersen L, Crino L et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a Phase II clinical trial. Ann. Oncol. 10, 1461-1465 (1999).
23. Stadler WM, Hayden A, von der Maase H et al. Long-term survival in Phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol. Oncol. 7(4), 153-157 (2002).
24. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin vs methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18, 3068-3077 (2000).
25. von der Maase H, Senegelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005).
26. Dash A, Pettus JA, Bochner BH et al. Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC). J. Clin. Oncol. 25(Suppl. 18), 5077 (2007).
27. Roth BJ, Dreicer R, Einhorn LH et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 12, 2264-2270 (1994).
28. Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 20(4), 937-940 (2002).
29. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 15(5), 1853-1857 (1997).
30. Dreicer R, Manola J, Roth BJ et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 18, 1058-1061 (2000).
31. Sengelov L, Kamby C, Lund B et al. Docetaxel and cisplatin in metastatic urothelial cancer: a Phase II study. J. Clin. Oncol. 16, 3392-3397 (1998).
32. Bellmunt J, Albanell J, Paz-Ares L et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a Phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95(4), 751-757 (2002).
33. Pectasides D, Glotsos J, Bountouroglou N et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a Phase II trial. Ann. Oncol. 13(2), 243-250 (2002).
34. Bajorin DF, McCaffrey JA, Dodd PM et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a Phase II trial evaluating two dosing schedules. Cancer 88(7), 1671-1678 (2000).
35. Dodd PM, McCaffrey JA, Hilton S et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J. Clin. Oncol. 18(4), 840-846 (2000).
36. Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107(3), 506-513 (2006).
37. Raj GV, Isasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J. Clin. Oncol. 24(19), 3095-3100 (2006).
38. Vaughn DJ, Manola J, Dreicer R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95(5), 1022-1027 (2002).
39. Linardou H, Aravantinos G, Efstathiou E et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 64(3), 479-484 (2004).
40. Bamias A, Moulopoulos LA, Koutras A et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. Cancer 106(2), 297-303 (2006).
41. Nogue-Aliguer M, Carles J, Arrivi A et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97(9), 21-80-2186 (2003).
42. Hussain M, Vaishampayan U, Du W et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 19(9), 2527 2533 (2001).
43. HainsworLh JD, Meluch AA, Litchy S et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103(11), 2298-2303 (2005).
44. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J. Clin. Oncol. 25(16), 2218-2224 (2007).
45. Galsky MD, Iasonos A, Mironov S et al. Phase II trial of close-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109(3), 549-555 (2007).
46. Boccardo F, Pace M, Guarnieri D et al. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A Phase II trial. Cancer 73(7), 1932-1936 (1994).
47. Dreicer R, Manola J, Schneider DJ et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97(11), 2743-2747 (2003).
48. Ardavanis A, Tryfonopoulos D, Alexopoulos A et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a Phase II study. Br. J. Cancer 92(4), 645-650 (2005).
49. Li J, Juliar B, Yiannoutsos C et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group study. J. Clin. Oncol. 23(6), 1185-1191 (2005).
50. Meluch AA, Greco FA, Burris HA III et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie pearl cancer research network. J. Clin. Oncol. 19(12), 3018-3024 (2001).
51. von der Maase H, Lehmann J, Gravis G et al. A Phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann. Oncol. 17(10), l533-1538 (2006).
52. Carles J, Esteban E, Climent M et al. Gemcitabine and oxaliplatin combination: a multicenter Phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann. Oncol. 18(8), 1359-1362 (2007).
53. Theodore C, Bidault F, Bouvet-Forteau N et al. A Phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann. Oncol. 17(6), 990-994 (2006).
54. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100(8), 1639-1645 (2004).
55. Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-fine chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase 2 trial. Eur. Urol. 52(1), 134-141 (2007).
56. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized Phase II study. Cancer 77(2), 344-351 (1996).
57. Bellmunt J, Ribas A, Eres N et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80(10), 1966-1972 (1997).
58. Boyer MJ, Gurney H, Rosenthal MA et al. Randomized Phase II study of gemcitabine (G) with either carboplatin (C) or docetaxel (D) in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium: preliminary results. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 1568).
59. Witte R, Elson P, Bono B et al. Eastern Cooperative Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol. 15, 589-593 (1997).
60. Krege S, Rembrink V, Borgermann C et al. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a Phase II study. J. Urol. 165, 67-71 (2001).
61. Sweeney CJ, Williams SD, Finch DE et al. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 86, 514-518 (1999).
62. Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J. Urol. 156(5), 1606-1608 (1996).
63. Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 20(4), 937-940 (2002).
64. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 15 (5), 1853-1857 (1997).
65. Vaishampayan UN, Faulkner JR, Small EJ et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma Southwest Oncology Group study. Cancer 104(8), 1627-1632 (2005).
66. Lorusso V, Pollera CF, Antimi M et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer 34(8), 1208-1212 (1998).
67. Albers P, Siener R, Hartlein M et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 25(1), 47-52 (2002).
68. Sternberg CN, Calabrò F, Pizzocaro G et al. Chemotherapy with every 2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92(12), 2993-2998 (2001).
69. Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol. 24(21), 3451-3457 (2006).
70. Galsky MD, Mironov S, Iasonos A et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest. New Drugs 25O(3), 265-270 (2007).
71. Culine S, Theodore C, De Santis M et al. A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br. J. Cancer 94(10), 1395-1401 (2006).
72. Dreicer R, Li S, Manola J et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the eastern cooperative oncology group. Cancer 110(4), 759-763 (2007).
73. Winquist E, Vokes E, Moore MJ et al. A Phase II study of oxaliplatin in urothelial cancer. Urol. Oncol. 23(3), 150-154 (2005).
74. Smith TJ, Khatcherissian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24(19), 3187-3205 (2006).